MX2009013069A - Tratamiento de leucemia resistente al imatinib. - Google Patents

Tratamiento de leucemia resistente al imatinib.

Info

Publication number
MX2009013069A
MX2009013069A MX2009013069A MX2009013069A MX2009013069A MX 2009013069 A MX2009013069 A MX 2009013069A MX 2009013069 A MX2009013069 A MX 2009013069A MX 2009013069 A MX2009013069 A MX 2009013069A MX 2009013069 A MX2009013069 A MX 2009013069A
Authority
MX
Mexico
Prior art keywords
treatment
resistant leukemia
imatinib resistant
imatinib
leukemia
Prior art date
Application number
MX2009013069A
Other languages
English (en)
Spanish (es)
Inventor
Becker Hewes
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009013069(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2009013069A publication Critical patent/MX2009013069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2009013069A 2007-06-01 2008-05-30 Tratamiento de leucemia resistente al imatinib. MX2009013069A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
PCT/US2008/065215 WO2008150957A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Publications (1)

Publication Number Publication Date
MX2009013069A true MX2009013069A (es) 2010-03-17

Family

ID=39639071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013069A MX2009013069A (es) 2007-06-01 2008-05-30 Tratamiento de leucemia resistente al imatinib.

Country Status (23)

Country Link
US (1) US11103497B2 (https=)
EP (4) EP2152267A2 (https=)
JP (3) JP5888853B2 (https=)
KR (1) KR101493543B1 (https=)
CN (1) CN101686973B (https=)
AU (1) AU2008260070B9 (https=)
BR (1) BRPI0812355A2 (https=)
CA (3) CA2964162C (https=)
CL (1) CL2008001577A1 (https=)
CY (2) CY1115251T1 (https=)
DK (2) DK2478905T3 (https=)
ES (2) ES2881391T3 (https=)
HU (1) HUE055524T2 (https=)
IL (1) IL202407A0 (https=)
MX (1) MX2009013069A (https=)
PA (1) PA8782301A1 (https=)
PL (2) PL2478905T3 (https=)
PT (2) PT2478905E (https=)
RU (1) RU2464026C2 (https=)
SI (2) SI2478905T1 (https=)
TW (1) TW200908982A (https=)
WO (1) WO2008150957A2 (https=)
ZA (1) ZA200908480B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2964162C (en) 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
RU2662810C2 (ru) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Хиназолины в качестве ингибиторов киназы
KR101733665B1 (ko) 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
PT2017335E (pt) 2001-10-05 2011-03-02 Novartis Ag Domínios da cinase abl mutados
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
DE602006014540D1 (en) * 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
EP1904654A2 (en) 2005-07-15 2008-04-02 Brystol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
BRPI0616923A2 (pt) 2005-10-06 2011-07-05 Lilly Co Eli anticorpos monoclonais, seus usos e composição farmacêutica
EP1948820A2 (en) * 2005-11-04 2008-07-30 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
CA2964162C (en) 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene

Also Published As

Publication number Publication date
SI3002009T1 (sl) 2021-09-30
RU2009144128A (ru) 2011-07-20
RU2464026C2 (ru) 2012-10-20
PA8782301A1 (es) 2009-01-23
IL202407A0 (en) 2010-06-30
HK1142812A1 (en) 2010-12-17
EP3002009A3 (en) 2016-07-06
BRPI0812355A2 (pt) 2015-01-27
CN101686973A (zh) 2010-03-31
CA2964162C (en) 2019-12-31
CY1124391T1 (el) 2022-07-22
EP3002009A2 (en) 2016-04-06
TW200908982A (en) 2009-03-01
EP2152267A2 (en) 2010-02-17
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
CY1115251T1 (el) 2017-01-04
CA2688467C (en) 2015-05-12
JP2010529038A (ja) 2010-08-26
EP2777704A2 (en) 2014-09-17
AU2008260070B2 (en) 2011-08-18
KR20100017983A (ko) 2010-02-16
CA2868899C (en) 2017-06-13
EP2478905A3 (en) 2013-01-16
ES2477567T3 (es) 2014-07-17
JP2016074700A (ja) 2016-05-12
AU2008260070B9 (en) 2012-01-19
ZA200908480B (en) 2010-08-25
US11103497B2 (en) 2021-08-31
CA2688467A1 (en) 2008-12-11
EP3002009B1 (en) 2021-07-07
CA2964162A1 (en) 2008-12-11
HUE055524T2 (hu) 2021-11-29
PL2478905T3 (pl) 2014-10-31
WO2008150957A3 (en) 2009-08-06
JP5888853B2 (ja) 2016-03-22
PL3002009T3 (pl) 2021-12-13
KR101493543B1 (ko) 2015-02-13
US20080318971A1 (en) 2008-12-25
SI2478905T1 (sl) 2014-07-31
CA2868899A1 (en) 2008-12-11
EP2478905B1 (en) 2014-05-14
AU2008260070A1 (en) 2008-12-11
PT2478905E (pt) 2014-07-16
JP2014111629A (ja) 2014-06-19
CN101686973B (zh) 2013-06-19
DK2478905T3 (da) 2014-06-30
WO2008150957A2 (en) 2008-12-11
EP2777704A3 (en) 2015-01-21
CL2008001577A1 (es) 2008-07-25
PT3002009T (pt) 2021-08-02
EP2478905A2 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
MX2009013069A (es) Tratamiento de leucemia resistente al imatinib.
TN2009000303A1 (en) Iron-hydrocarbon complex compounds
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
AU2009313134A8 (en) Novel halogen-substituted compounds
UA110338C2 (xx) Хімічні сполуки
MX2010009026A (es) Uso de compuestos que se enlazan a los ligandos del receptor sigma para el tratamiento de dolor neuropatico que se desarrolla como una consecuencia de la quimioterapia.
UA107796C2 (en) Tetracyclic compound
JO2860B1 (en) Phenylendazolyl compounds
MX2012001156A (es) Moleculas que contienen boro trisustituidas.
TN2011000291A1 (en) Purine compounds
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX2009005649A (es) Tratamiento para mieloma multiple.
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MY150600A (en) Use of opioid antagonists for treating urinary retention
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
NZ593172A (en) 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2010004592A (es) Metodo mejorado para producir diesteres.
MX2009009490A (es) Profarmacos novedosos.
MX2012008125A (es) Herramienta para el recubrimiento electrolitico de cojinetes de deslizamiento.
PH12017500270A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain

Legal Events

Date Code Title Description
FG Grant or registration